The FDA approved mFLUSIVA on August 5, 2026 — the first flu vaccine in U.S. history built on mRNA technology. Moderna got full approval for adults 50-64. Adults 65 and up got accelerated approval only, pending a two-season post-market trial. In the Phase 3 study across 40,000 participants in 11 countries, mFLUSIVA was about 27% more effective at preventing confirmed influenza-like illness than a standard-dose flu shot. The FDA's own advisory panel voted 9-0 that the benefits outweigh the risks — twice, once for each age group. Moderna expects the vaccine to be available for the 2026-2027 flu season.

1. The vaccine works (Vaccine Advocates, Dr. Jeanne Marrazzo, Dr. Céline Gounder)

This camp says mFLUSIVA cleared the highest evidentiary bar the FDA sets, and deployment should start now.

mFLUSIVA is about 27% more effective than a standard flu shot. That's not a marginal improvement — it comes from a 40,000-person global trial. The FDA's advisory panel voted 9-0 that the benefits outweigh the risks, both for people 50-64 and for adults 65 and older. Dr. Jeanne Marrazzo, CEO of the Infectious Diseases Society of America, called it "a historic event and incredibly exciting, both scientifically and from a public-health standpoint."

Manufacturers can update mRNA flu vaccines in months, not 18. Traditional egg-based shots take about 18 months from strain selection to rollout. Dr. Céline Gounder, CBS News's medical correspondent, says manufacturers can turn around mRNA vaccines much faster — a critical edge in a pandemic.

The mRNA platform has proven itself well beyond flu. Jeff Coller, a professor at Johns Hopkins, points to melanoma therapies showing a 49% reduction in recurrence risk. He also cites pancreatic cancer patients with near-90% six-year survival in early trials. Rick Bright, a former BARDA director, warned that dismantling mRNA programs is gutting America's defenses against biological threats.

2. But the trial used the wrong benchmark (MAHA Skeptics, Robert F. Kennedy Jr.)

This camp says the 27% efficacy figure is misleading, and politics drove the FDA's reversal, not science.

The benchmark was wrong. Former FDA biologics chief Vinay Prasad rejected the application in February 2026 on exactly these grounds: Moderna used a standard-dose comparator for a population that's supposed to get high-dose or adjuvanted vaccines. The FDA had told Moderna beforehand that those were the appropriate benchmarks for adults 65 and older. Moderna measured that 27% advantage against a shot most elderly patients wouldn't be getting anyway.

The FDA reversed Prasad's rejection within a week, under public pressure. Commissioner Marty Makary overruled him, calling the initial rejection "part of a conversation that occurs with all drug makers." Prasad left the FDA by April 2026. Dr. Marrazzo herself said it was "hard to read as anything other than a political decision from above."

The administration had already written off the mRNA platform for respiratory viruses. Kennedy canceled 22 mRNA vaccine projects worth $500 million in August 2025, saying the data showed they "fail to protect effectively against upper respiratory infections like Covid and flu." The Trump administration also revised federal vaccination guidance in January 2026, shifting from universal flu vaccine recommendations to individual patient decisions. One FDA approval hasn't changed that posture. And for adults 65 and older, the approval is still accelerated — the confirmatory trial data isn't in.

3. And approval doesn't mean coverage (Access Advocates, Jennifer Kates / KFF)

This camp says most Americans under 65 have no guarantee of zero-cost access, because of a federal advisory committee that's legally paralyzed.

Private insurers aren't required to cover mFLUSIVA. Under the ACA, private plans must cover vaccines at zero cost only when ACIP — the Advisory Committee on Immunization Practices — recommends them. ACIP has not recommended mFLUSIVA. AHIP, the health insurance trade group, committed to covering vaccines that were on the ACIP list as of September 1, 2025. mFLUSIVA didn't exist then, so it's not on that list.

A court order has frozen ACIP. A federal district court in Massachusetts stayed the committee's reconstitution in March 2026, ruling that Kennedy's decision to fire all 17 sitting members likely violated federal advisory law. ACIP's next scheduled meeting is October 2026 — after flu season kicks into gear.

Medicare covers mFLUSIVA. Private insurance plans don't have to. Jennifer Kates, senior vice president at KFF, confirmed that Medicare will cover the shot. For Americans under 65 on private plans, coverage will depend on their insurer — and nothing currently requires the shot to be free.

Where This Lands

Doctors see the approval as settled. A 40,000-person global trial and two unanimous expert votes are hard to argue against. The MAHA camp isn't moving. Kennedy's $500 million cancellation of mRNA research predates the approval, and his position hasn't changed. The comparator question — was standard-dose the right benchmark for elderly patients? — is still live. For most Americans under 65, the immediate question isn't who's right on the science — it's whether their insurer covers mFLUSIVA before the ACIP committee meets in October.

Sources